The rotigotine transdermal patch (RTP) is a dopamine agonist used to treat Parkinson’s disease (PD). Some PD patients cannot continue RTP treatment due to application site reactions. We explored sites for RTP where application site reactions are less severe than those in the six approved application sites. Thirty PD patients (12 men, mean age = 76 years) who underwent RTP at the approved sites and had some application site reactions were enrolled in this study. When applying the RTP to the approved application sites for more than four weeks (pre-RTP) and then on the shin for the following four weeks (post-RTP), skin reactions, itching evaluated using the skin irritation score, motor symptoms, clinical global impressions scale, and plasma rotigotine concentration were examined. The mean visual analogue scale and skin irritation score in the post-RTP group were significantly lower than those in the pre-RTP group. The mean Movement Disorder Society-Unified Parkinson’s Disease Rating Scale part III score in the post-RTP group was slightly but significantly lower than that in the pre-RTP group. Plasma rotigotine concentration in the post-RTP group was slightly but significantly lower than that in the pre-RTP group. These results indicate that the shin can be a useful application site for RTP.

中文翻译：

---

罗替戈汀透皮贴剂扩大应用部位的研究。

罗替戈汀透皮贴剂（RTP）是一种多巴胺激动剂，用于治疗帕金森氏病（PD）。一些PD患者由于应用部位反应而无法继续进行RTP治疗。我们探索了RTP的站点，这些站点的应用程序站点响应比六个批准的应用程序站点严重。这项研究招募了30例PD患者（12名男性，平均年龄= 76岁），这些患者在批准的部位接受了RTP治疗，并有一些应用部位的反应。当将RTP应用于批准的应用部位超过四周（RTP之前），然后在胫骨上进行接下来的四周（RTP之后）时，使用皮肤刺激性评分，运动症状，临床评估皮肤反应，瘙痒检查整体印象量表和血浆罗替戈汀浓度。RTP后组的平均视觉模拟量表和皮肤刺激评分显着低于RTP前组。RTP后组的平均运动障碍协会统一的帕金森氏疾病评分量表第III部分得分略低于但显着低于RTP前组。RTP后组的血浆罗替戈汀浓度略低于但显着低于RTP前组。这些结果表明，胫骨可以成为RTP的有用应用站点。RTP后组的血浆罗替戈汀浓度略低于但显着低于RTP前组。这些结果表明，胫骨可以成为RTP的有用应用站点。RTP后组的血浆罗替戈汀浓度略低于但显着低于RTP前组。这些结果表明，胫骨可以成为RTP的有用应用站点。